First human trial for new drug ORKA-001 begins safety check
NCT ID NCT06698939
First seen Apr 02, 2026 · Last updated Jun 22, 2026 · Updated 12 times
Summary
This early-phase study tested a single injection of ORKA-001 in 24 healthy adults to see if it is safe and how the body processes it. Participants were randomly assigned to receive either the drug or a placebo. The main goal was to check for side effects and changes in vital signs, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Oruka Therapeutics Investigative Site
Christchurch, New Zealand
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORKA-001
What could go wrong
This is an early, small study in healthy people, so it cannot show if ORKA-001 works for any disease. Side effects are possible but unknown.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.